TAM resistance in breast cancer is driven by RelB, which inhibits TAM-induced ferroptosis by upregulating GPX4, and that reducing RelB or GPX4 levels can resensitize TAM-resistant cells by promoting ferroptosis. This evidence concerns the gene RELB and breast carcinoma.